FDA advisory panel backs new opioid addiction drug

1 November 2017

Shares of UK-listed Indivior (LSE: INDV) gained 11.28% to 413.50 pence in early trading this morning, following a positive outcome of a US Food Administration advisory panel vote on the firm's investigational drug RBP-6000.

Indivior, which was spun out of Reckitt Benckiser in 2014 and operates out of Virginia, USA, announced today that the Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee of the FDA voted 18 to 1 to recommend approval of RBP-6000 for the treatment of opioid use disorder (OUD).

“I think this is a really promising alternative to what’s out there and will be attractive to a lot of patients,” said Laurel Habel, one of the panelists and researcher at Kaiser Permanente in Oakland, California.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK